Interactions of graphene with mammalian cells: Molecular mechanisms and biomedical insights  by Zhang, Bo et al.
Advanced Drug Delivery Reviews 105 (2016) 145–162
Contents lists available at ScienceDirect
Advanced Drug Delivery Reviews
j ourna l homepage: www.e lsev ie r .com/ locate /addrInteractions of graphene with mammalian cells: Molecular mechanisms
and biomedical insights☆Bo Zhang a,1, Peng Wei a,b,1, Zhixiang Zhou c,1, Taotao Wei a,⁎
a National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
b University of Chinese Academy of Sciences, Beijing 100049, China
c College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, ChinaAbbreviations: ATP, adenosine triphosphate; CDDP, ci
electron spin resonance; EA, electron afﬁnity; ECM, cell-e
macrophage colony-stimulating factor; GO, graphene oxid
tumdot; GO-NH2, aminated GO; GO-PAM, poly(acrylamid
guanosine triphosphate hydrolase; HPV, human papillom
monocyte chemotactic protein; MIP, macrophage inﬂamm
adenine dinucleotide; OXPHOS, oxidative phosphorylation
nanosheet; RANTES, regulated on activation, normal T cel
acids in cell culture; TCA, tricarboxylic acid cycle; TEM, tr
☆ This review is part of the Advanced Drug Delivery Revi
⁎ Corresponding author.
E-mail address: weitt@moon.ibp.ac.cn (T. Wei).
1 BZ, PW, and ZZ contributed equally to this work.
http://dx.doi.org/10.1016/j.addr.2016.08.009
0169-409X/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 14 March 2016
Received in revised form 18 August 2016
Accepted 22 August 2016
Available online 26 August 2016Carbon-based functional nanomaterials have attracted immense scientiﬁc interest frommany disciplines and, due
to their extraordinary properties, have offered tremendous potential in a diverse range of applications. Among the
different carbon nanomaterials, graphene is one of the newest and is considered the most important. Graphene, a
monolayer material composed of sp2-hybridized carbon atoms hexagonally arranged in a two-dimensional
structure, can be easily functionalized by chemical modiﬁcation. Functionalized graphene and its derivatives
have been used in diverse nano-biotechnological applications, such as in environmental engineering, biomedicine,
and biotechnology. However, the prospective use of graphene-related materials in a biological context requires a
detailed comprehension of these materials, which is essential for expanding their biomedical applications in the
future. In recent years, the number of biological studies involving graphene-related nanomaterials has rapidly
increased. These studies have documented the effects of the biological interactions between graphene-related
materials and different organizational levels of living systems, ranging frombiomolecules to animals. In the present
review, we will summarize the recent progress in understanding mainly the interactions between graphene and
cells. The impact of graphene on intracellular components, and especially the uptake and transport of graphene
by cells, will be discussed in detail.
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Graphene is a single layer of carbon packed in a hexagonal
(honeycomb) lattice with carbon–carbon distances of 0.142 nm. It
was ﬁrst isolated by Andre Geim and Konstantin Novoselov, the 2010
laureates of the Nobel Prize in Physics, from its three-dimensional par-
ent material, graphite [1]. Since then, this research area has exploded,
producing a rapidly growing number of papers concerning graphene
and graphene-related materials (Fig. 1) [2], including few layer
graphene (FLGS), ultrathin graphite, graphene oxide (GO), reduced
graphene oxide (rGO), and graphene nanosheets.
Graphene and graphene-related nanomaterials have attracted
tremendous attention and research interest owing to their physical
properties, such as their exceptionally large surface area, high electronic
conductivity, good thermal stability, and excellent mechanical strength
[2]. They have a wide range of potential applications in electronics and
optoelectronics [3,4], energy conversion [5,6] and storage [7], catalysis
[8,9], and environmental applications [10]. Recently, the biological
applications of graphene and graphene-related nanomaterials have
attracted attention in the scientiﬁc community based on their great
potential for use in bio-imaging [11,12], cancer theragnosis [13–15],
gene delivery [16], tissue engineering [17,18], biosensing [19], DNA se-
quencing [20], and drug delivery [21–23]. Several reviews have summa-
rized the applications of graphene-related nanomaterials in biology and
medicine [24–29].
Graphene-related nanomaterials have now been developed inmany
different forms in terms of their shapes, sizes, and surfacemodiﬁcations,
which endow them with versatile physical, chemical, and biomedical
characteristics. In vitro cytotoxicological investigations are required in
order to develop graphene-related biomedicalmaterials, and systematic
evaluations of the biocompatibility of graphene-related materials
are essential before their application in vivo. Since 2008, numerousFig. 1. Structure of graphene, graphene oxide (Gstudies have investigated the nanotoxicology and biocompatibility of
graphene-related materials, and several reviews have been published
[25,30,31]. However, how graphene-related materials perform these
biomedical effects is still not clearly summarized; there is still a lack of
a systematic review on the interaction between graphene and biological
systems at the cellular level. In this paper, we aim to summarize the
recent research advances in this ﬁeld. We begin by reviewing three
systems biology-based studies on the biological effects of graphene in
different cell types. By assessing the omics data with Gene Ontology
analyses, Path-Net analyses, and other bioinformatics approaches, we
show that graphene and its derivatives impact the cell components,
especially the plasmamembrane and themembrane organelles, and in-
terferewith the cellularmetabolism. Next, we discuss how the structure
and function of the plasma membrane, lysosomes, mitochondria, and
other cellular components are affected by graphene. Considering the
application potential of graphene as drug or gene carriers, we discuss
in detail the interactions between graphene and certain types of cells,
including hemocytes, blood vessel endothelial cells,macrophages, cancer
cells, and stem cells.2. Systemsbiology-based analyses of the biological effects of graphene
Systems biology approaches based on integrated omics and bioinfor-
matics analyses have undergone rapidly and could be used as powerful
tools to explore the interactions between nanomaterials and biosystems.
Chatterjee and coworkers proﬁled the gene expression at the mRNA
level in HepG2 hepatoma cells treated with graphene oxide (GO). The
differential gene expression of a normalized microarray analysis
revealed that 1224 genes were induced or repressed by more than
1.5-fold under GO treatment. The Gene Ontology analysis indicated
that genes related to the regulation of cell growth and apoptosis, theO) and reduced graphene oxide (rGO) [2].
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regulated as a result of GO treatment [32].
Zhou and coworkers also investigated the effects of GO onMDA-MB-
231 breast cancer cells by evaluating the gene expression at the protein
level. Using the SILAC (stable isotope labeling by amino acids in cell cul-
ture) method, they quantiﬁed the protein expression in both breast
cancer cells and non-cancerous cells, identifying and quantifying a
total of 2254 cellular proteins expressed in breast cancer cells (Fig. 2).
Based on a cutoff value of 1.2, 168 proteins were found to be up-
regulated and 685proteinswere down-regulated byGO.GeneOntology
and Path-Net analyses indicated that multiple proteins involved in
metabolic processes, the regulation of cell growth, and apoptosis wereB
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terms classiﬁed into several categories, including the regulation of
cell growth and apoptosis, inﬂammation, metabolic processes, and
development [34].
In these three researchworks, geneswhose expression proﬁleswere
signiﬁcantly altered in GO samples comparing to normal samples have
been identiﬁed. The relationship among those differentially expressed
genes and how they work coordinately as a molecular group have also
been further analyzed, which construct or imply us the GO–cell interac-
tions, GO-organelle interactions, and protein–protein interactions. The
results indicated that graphene and its derivatives affect the cellular
components, especially the plasma membrane, cytoskeleton, and the
membrane organelles (including the mitochondrion, lysosome, and
nucleus). GO treatment alters the metabolic processes, impacts cell
growth, and induces apoptosis at higher concentrations.Wewill review
these biological effects in detail below.
3. Interactions between graphene and the plasma membrane
Graphene and graphene-related nanomaterials have attracted great
interest in nanomedicine due to their intrinsic properties. Interactions
at the interface of graphene and mammalian cells must be considered
in studies assessing the use of graphene in biomedical applications;
some studies have shown that the internalization of graphene is a
mechanism that can lead to cell intoxication, while other studies have
shown that graphene internalization can transport therapeutic agents
intracellularly without ensuing damage. Thus, graphene internalization
may cause completely different effects on different cell types.
Researchers should carefully consider the chemical and physical prop-
erties of graphene as well as the cellular context when they design
graphene-based nanomaterials [35]. Here, we summarize the recent
progress in understanding the internalization of graphene and
graphene-related nanomaterials by mammalian cells, the impact on
the integrity of the plasma membrane, and the interaction between
graphene and biomolecules.
3.1. Internalization of graphene across the plasma membrane
Like other nano-sized substances, graphene and graphene-related
nanomaterials are primarily internalized into cells via endocytosis,
which can be subdivided into four categories: clathrin-mediated
endocytosis, caveolae-mediated endocytosis, macropinocytosis, and
phagocytosis. Notably, the internalization of graphene into cells is
known to be related to the cell type. Linares and coworkers investigated
the impact of eight inhibitors (colchicine, wortmannin, amiloride, cyto-
chalasin B, cytochalasin D, genistein, phenylarsine oxide, and chlor-
promazine) that speciﬁcally affect different endocytotic mechanisms
on the cellular uptake of GO nanosheets by three different cell types
(Saos-2 osteoblasts, HepG2 hepatoma cells, and RAW-264.7 macro-
phages). They found that macropinocytosis seems to be a general inter-
nalization process in the three cell lines analyzed. In addition, GO can
enter Saos-2 cells through microtubule-dependent pathways and
HepG2 and RAW-264.7 cells through clathrin-dependent mechanisms
[36].
The internalization of graphene-related nanomaterials into cells is
strongly inﬂuenced by the particle size. A study with protein-coated
GO nanosheets showed that small GO enter cells primarily through
clathrin-mediated endocytosis; increasing the size of GO enhances
their phagocytotic uptake [37]. Surface chemistry also inﬂuences the
internalization of graphene-related materials [38,39]. Chatterjee and
coworkers reported that GO could be internalized by HepG2 cells; on
the contrary, reduced GO (rGO), which is much more hydrophobic in
comparison with GO, was found to mostly adsorb onto the cell surface
without internalization [32]. However, in certain types of cells, both
GO, and rGO ﬂakes of different sizes could be taken up effectively by
cells via the endocytic pathway [40].Scientists couldmanipulate the internalization of graphene viamod-
ulation of the particle size and surface chemistry. The internalization of
graphene nanoribbon (GNR) derived from the longitudinal unzipping
carbon nanotubes has been investigated systematically in different cell
types [39,41]. Chowdhury and coworkers show that functionalized
GNR activate epidermal growth factor receptors (EGFRs). This activation
generates a predominantly dynamin-dependent macropinocytosis-like
response and results in signiﬁcant GNR uptake into cells with high
EGFR expression. Cells with an integrated human papillomavirus
(HPV) genome also show increased uptake due to the modulation of
the activated EGFR by the viral protein E5. Thus, this cell-speciﬁc uptake
of GNR can be exploited to achieve signiﬁcantly enhanced drug efﬁca-
cies even in drug-resistant cells. These results have implications for
the development of active targeting and delivery agents for use in the
diagnosis and treatment of pathologies [42]. For example, functional-
ized GNR could be used as an efﬁcient agent for delivery of anti-tumor
drug lucanthone into glioblastoma multiforme (GBM) cells targeting
base excision repair enzyme apurinic endonuclease-1 [43].
The dynamics of the internalization of graphene can be traced by cell
imaging-based experiments and computational simulation-based in
silico approaches. Li and coworkers investigated the interactions be-
tween graphene and model lipid bilayers by combining coarse-grained
molecular dynamics (MD), all-atom molecular dynamics, analytical
modeling, confocal ﬂuorescence imaging, and electron microscopic
imaging. The imaging experiments showed edge-ﬁrst uptake and the
complete internalization of a range of graphene and few layer graphene
(FLG) samples of 0.5- to 10-μm in the lateral dimension. Computational
simulations indicated that the entry of graphene and FLG is initiated at
corners or asperities, which are abundant along the irregular edges of
fabricated graphene materials. Local piercing by these sharp protrusions
initiates membrane propagation along the extended graphene edge,
thereby avoiding the high energy barrier. These ﬁndings provide a funda-
mental understanding of interactions at the interface of two-dimensional
nanostructures and biological systems (Fig. 3) [44].
3.2. Impacts on the dynamics and integrity of the plasma membrane
Although low concentrations of graphene and graphene-related
nanomaterials show little or no toxicity in mammalian cells, high
concentrations of graphene alter the dynamics and integrity of the
plasma membrane during their internalization, and induce cell death.
Liao and coworkers investigated the effects of graphene on human
erythrocytes and found that nano-sized graphene (350 nm) could
induce severe hemolysis compared to micro-sized (3 μm) graphene
sheets [45]. They suggested that the serious membrane disruption by
nano-sized graphene might be attributed to the strong electrostatic
interactions between the graphene surface and the lipid bilayer of the
erythrocyte membrane. By contrast, the relatively low toxicity of micro-
sized graphene sheets may have been due to their lower overall surface
areas.
Graphene also impacts the integrity of the plasma membrane in
other mammalian cells. Li and coworkers reported that exposure of
GLC-82 lung cancer cells to GO for 48 h induced the redistribution of
cytoplasmic lactate dehydrogenase (LDH), suggesting the signiﬁcant
loss of plasma membrane integrity [34]. Similar results have been
observed in other cell types, including MCF-7 breast cancer cells, Panc-1
pancreatic cancer cells [46], and MDA-MB-231 breast cancer cells [47],
implying that the exposure of cells to high concentrations of graphene
damages the membrane integrity. Accordingly, blocking the internaliza-
tion of graphenewith endocytosis inhibitors has been shown to attenuate
the graphene-induced plasma membrane damage [32]. Lammel and
coworkers observed the impact of graphene on the ultrastructure of the
plasma membrane and found that nano-sized graphene penetrates the
plasmamembrane (Fig. 4). They showed that at the site of interaction be-
tween the graphene nanoplatelet and the plasmamembrane, membrane
invagination and some disruption of the plasma membrane occur. At
Fig. 3. Dynamics of the interaction between graphene and membrane systems. (A–H) Coarse-grained molecular dynamics simulations of interactions between a lipid bilayer. (A–D) and
(F–H) are time sequences; (E) is an experimental graphene edge structure. (I) The normalized free energy of the system as a function of the graphene orientationwhen one of the sharpest
corners isﬁxed at a distanceof 0.5 nmabove the bilayer. The results of themolecular dynamics simulations indicated that the entry of graphene across themembrane systems is initiated at
corners or asperities. Local piercing by these sharp protrusions initiates membrane propagation along the extended graphene edge, thereby avoiding the high energy barrier. Image
adapted from Reference [44] with permission, copyright © HighWire Press, Inc. 2014.
149B. Zhang et al. / Advanced Drug Delivery Reviews 105 (2016) 145–162graphene nanoplatelet concentrations of 8 μg/ml and lower, only a
portion of the cell surface interacted with the graphene platelets. While
the micro-sized graphene platelets were retained by the microvilli, the
nano-sized platelets were deposited onto the microvilli-free plasma
membrane domains [48].Fig. 4. Interaction between GOnanoplatelets with the plasmamembrane of HepG2 cells. (A) SEM
arrows) with the plasma membrane (pm) and microvilli (mv). (B) SEMmicrographs showing
membrane (arrow with white asterisk). (C) Membrane invagination (white arrow) at th
(D) Disruption of the plasma membrane (black asterisk) at the site of interaction with GO nan
B, and 500 nm in (C) and (D). Black arrows exemplarily indicate GO nanoplatelets. mt: mito
with permission, copyright © BioMed Central Ltd. 2013.Graphene also inﬂuences the membrane integrity and dynamics via
indirect mechanisms. The in vitro experiments by Xu and coworkers
revealed that pristine GO could impair cell membrane integrity and
functions by regulation of membrane- and cytoskeleton-associated
genes, including Actg2, Myosin, Tubb2a, and Nebulin [49]. Matesanzmicrograph showing the interaction of GOnanoplatelets (exemplarily indicated by black
the boxed-in area in A at higher magniﬁcation. GO nanoplatelet penetrating the plasma
e site of interaction of a GO nanoplatelet (black arrow) with the plasma membrane.
oplatelets (exemplarily indicated by black arrows). Scale bars represent 200 nm in A and
chondrion, pm: plasma membrane, mv: microvilli. Image adapted from Reference [48]
150 B. Zhang et al. / Advanced Drug Delivery Reviews 105 (2016) 145–162and coworkers also demonstrate that, after internalization, GO
nanosheets are localized on F-actin ﬁlaments and thus induce cell cycle
alterations, apoptosis, and oxidative stress in mammalian cells [50].
The size of graphene-related materials inﬂuences their impact on
plasma membrane signiﬁcantly. Akhavan and coworkers synthesized
reduced graphene-oxide nanoplatelets (rGONPs) and evaluated the
size-dependent toxicity on the mesenchymal stem cells (MSC). The
cell viability test showed signiﬁcant cell destructions by 1.0 μg/mL
rGONPs with average lateral dimensions (ALDs) of 11 ± 4 nm, while
the rGO sheets with ALDs of 3.8 ± 0.4 μm could exhibit a signiﬁcant cy-
totoxic effect only at high concentration of 100 μg/mL after 1 h exposure
time [51].
The shape of the nano-sized graphene impacts their effects on the
integrity of cell membranes. Chng and coworkers compared the cyto-
toxicity of graphene-oxide nanoribbons (GONRs) and graphene-oxide
nanoplatelets (GONPs). In vitro assessments revealed that the GONRs
exhibited a much stronger cytotoxicity over the GONPs. In comparison
with GONPs derived from graphite using Hummer's method, GONRs
derived from the longitudinal unzipping carbon nanotubes are often
larger, more oxidized, and differently shaped. The high aspect ratio and
the greater amount of carbonyl groups of GONR might be the related
with its higher cytotoxicity [52].
Surface chemistry also inﬂuences the graphene–membrane interac-
tions. By combining large-scale computational simulations, theoretical
analyses, and experimental investigations, Mao and coworkers evaluat-
ed the interactions between graphene nanosheets with varying degrees
of oxidation and a model lipid bilayer membrane. They found that the
perturbation degree of the lipid bilayer membrane increases with
increasing the edge length of nanosheet at each oxidization degree.
With the graphene oxidization degree increased, themembrane pertur-
bation becomes more irregular while the perturbation range becomes
wider. Graphene nanosheets tend to pierce the membrane and to take
a conﬁguration vertical to the membrane with the increase of
oxidization degree. From an energy perspective, the energy due to the
repulsion between lipid tails and oxidized graphene beads can be signif-
icantly reduced when the oxidized basal plane deviates away from the
center of bilayer membrane. However, the pierced membrane losses
its integrity and presents a large scale of irregular perturbation, corrob-
orating the observation of the thickness ﬁeld. These results imply that a
graphene nanosheet with larger size and higher oxidization degreemay
lead to stronger cytotoxicity [35]. These data not only provide new
mechanistic insight into how the cellular internalization of graphene-
based nanomaterials occurs but also offer a fundamental understanding
of the physicochemical properties of these materials, which can be
precisely tailored for safer biomedical applications.
4. Impact of graphene on intracellular organelles
After its internalization, graphene is entrapped within the endo-
some/lysosome system. Using the endosome/lysosome as the basement
of intracellular interactions, graphene interacts with other intracellular
organelles and machineries and triggers cellular responses. Here, we
summarize the impact of graphene on important intracellular organ-
elles and machineries, including lysosomes, mitochondria, nuclei, and
the cytoskeleton system, which will be helpful for the understanding
of the bio-effects of graphene at the cellular level.
4.1. Impact on lysosome-related organelles
As mentioned above, graphene is mainly internalized by cells via
endocytosis. Thus, the endosome/lysosome system is pivotal to the
intracellular transportation and entrapment of graphene. Li and co-
workers reported that GO and GO nanoassemblies are mainly distributed
in acidic lysosomes of mouse embryonic ﬁbroblasts (MEF) after their
internalization [53]. Similar results have also been reported in 4T1 breast
cancer cells by Chen [54]. The conjugation of a bulky ﬂuorophore tographenemay alter its surface chemistry and thereby interferewith its in-
ternalization and translocation. However, graphene can be visualized
under a ﬂuorescence microscope by quenching the emission from a dye
[55]. To detect the presence of graphene in the lysosomes, MDA-MB-
231 breast cancer cells were stained with a lysosome-speciﬁc ﬂuores-
cence probe. The results based on a 3D-reconstruction of confocal images
clearly indicated that the ﬂuorescence of the lysosomes could be partially
quenched by graphene, suggesting that graphene nanoparticles were
near or inside the lysosomes [56].
Graphene nanostructures with lysosome-targeting properties have
shown potential applications in biomedicine, especially as drug carriers.
Zeng and coworkers constructed a graphene-based, lysosome-targeting
delivery system in which nanographene (NGO, 20–40 nm) particles
were modiﬁed by covalent functionalization with a linear chain of
PEG. The photosensitizer molecule Chlorin e6 (Ce6) was loaded onto
the NGO-PEG particles via π-π stacking and hydrophobic interactions.
By using this nanoplatform, a photosensitizer could be selectively
translocated into the lysosomes, which signiﬁcantly enhanced the
efﬁcacy of photodynamic therapy [57].
The inﬂuence of graphene on lysosomes is concentration dependent.
Low concentrations of graphene shows little to no effects on the integ-
rity of the lysosomal membrane and thus do not inﬂuence the cell
viability. However, high concentrations of graphene cause lysosomal
membrane permeabilization, which results in cell death via different
pathways, including lysosome/mitochondria-dependent apoptosis
[58], lysosome-dependent necrosis, and lysosome-dependent autopha-
gic cell death. Recently, the impact of graphene on the autophagic
machinery has attracted increased attention. Autophagy and autophagic
cell death have been recently recognized as important lysosome-based
cell death pathways, and autophagosome accumulation has been found
to be associated with exposure to various nanoparticles. However, the
underlying mechanisms are still uncertain because autophagosome ac-
cumulation can result from autophagy induction and/or an autophagy
blockade. GO can induce autophagosome accumulation and the conver-
sion of LC3-I to LC3-II, as evidenced by the inhibitory effect of graphene
oxides on the degradation of the p62 protein, an autophagic substrate.
Further analyses of lysosomes revealed that graphene oxides accumulate
in macrophage lysosomes and lead to lysosome membrane destabiliza-
tion, which indicates reduced autophagic degradation [59]. As the effects
of GO on cell lysosomes and autophagy reveal a potentially toxic
mechanism, caution is recommended in the utilization of GO.
4.2. Impact on mitochondria
Mitochondria function as signaling hubs that are essential for
maintaining aspects of physiology, such as the cellular energy balance,
metabolism, and themodulation of calcium signaling. Themitochondria
also deﬁne the cellular redox balance, regulate important biosynthetic
pathways, and act as sensors and ampliﬁers of cellular damage. Thus,
the mitochondria play crucial roles in the induction of cell death. Re-
cently, we and other groups have found that graphene and graphene-
related nanomaterials can interact with the mitochondria, modulating
their morphology and function. Because the mitochondria are closely
related to the survival, differentiation, and death of cells, exploring
the mechanisms that underlie the interactions between graphene and
mitochondria will be of great value.
4.2.1. Decrease of membrane potential
Internalized graphene is mainly entrapped within the lysosome.
However, a small proportion of graphene can relocate to the cytosol,
where it can interact with the mitochondria, as evidenced by the
ﬂuorescence quenching assay [56]. Similar results were also reported
by Li and coworkers, who used transmission electron microscopy
(TEM) to observe the accumulation of GO within the cytosol and
mitochondria [34].
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mitochondrial membrane potential (MMP) is crucial to ATP synthesis.
The MMP decreases in response to graphene treatment. Lammel and
coworkers reported that exposing cells to GO results in the perturbation
of the mitochondrial structure and function, as characterized by a
decrease in themitochondrial membrane potential and the dysregulation
of mitochondrial Ca2+ homeostasis [48]. Similar to nano-sized GO,
pristine graphene [32] and graphene quantum dots [60] also caused
time- and concentration-dependent decreases in the mitochondrial
membrane potential.
The maintenance of the MMP is dependent on the oxidation of
various substances catalyzed by electron transfer chain (ETC) complexes:
complex I and complex II (succinate dehydrogenase) catalyze the transfer
of electrons from NADH and FADH to coenzyme Q, respectively. Coen-
zyme Q then transfers electrons to complex III, which passes them to
cytochrome c, which in turn donates electrons to complex IV. The passage
of electrons between the donors and acceptors generates a proton gradi-
ent across the mitochondrial membrane, which complex V utilizes for
ATP synthesis. Through a combination of confocal microscopy, ﬂow cy-
tometry, and enzymatic activity assays, Zhou and coworkers provided di-
rect evidence that exposing cells to graphene leads to the direct inhibition
of the ETC complexes I, II, III, and IV, resulting in the depolarization
of mitochondria and the consequent impairment of ATP production
(Fig. 5) [56].
4.2.2. Induction of ROS generation
Mitochondrial depolarization is also associated with mitochondrial
dysfunction and the overproduction of reactive oxygen species (ROS)
[48,61]. These processes have been suggested to be themainmechanisms
underlying graphene toxicity in mammalian cells [62]. Li and coworkers
found that pristine graphene causes a decrease in the MMP and, conse-
quently, increased levels of intracellular ROS, which activate the
mitochondria-dependent apoptotic pathway. These ﬁndings were evi-
denced by the permeablization of the mitochondrial outer membrane,
the redistribution of mitochondrial cytochrome c, and the activation of
caspases, which ultimately resulted in cell death [58].
The mechanisms underlying the graphene-induced decrease in the
membrane potential, the impairment of ATP production, and the over-
production of ROS have been partially explored by several groups.
Duch and coworkers suggested that GO might act as an electron
donor, which increases the supply of electrons to complexes I and II of
the electron transport chain (ETC) and accelerates the generation of
ROS as a byproduct of mitochondrial respiration. However, the increase
in oxygen consumption was not induced by treatment with pristineFig. 5. The impairment of the mitochondrial energy production by graphene. Graphene
directly inhibits the activity of electron transfer chain complexes by disturbing electron
transfer. This leads to decreased mitochondrial membrane potential and reduced ATP
synthesis. Image adapted from Reference [56] with permission, copyright © Elsevier B.V.
2014.graphene, suggesting that the production of ROS by electron donation
depends on the chemical characteristics of graphene [63]. By using the
nematode as a model system, Zhang and coworkers suggested that GO
triggers the overproduction of hydroxyl radicals and the formation of
oxidizing cytochrome c intermediates, which are responsible for the
oxidative stress [64]. They further compared the effects of GO with dif-
ferent degrees of oxidation on the production of ROS in mammalian
cells, ﬁnding that GO stimulated a dramatic enhancement of ROS pro-
duction and that GOparticleswith less oxidation produced higher levels
of ROS. The results of electron spin resonance (ESR) spectrometry
showed that lower degrees of GO oxidation were strongly associated
with greater indirect oxidative damage through facilitating H2O2
decomposition into hydroxyl radicals as well as with higher direct
oxidative abilities on cells. The theoretical simulation revealed that
carboxyl groups and the sizes of aromatic domains in nanosheets had
critical effects on the energy barrier of the H2O2 decomposition reaction
[65].
The ability of graphene to induce ROS production is also related to its
size [66]. By combining ESR spectrometry and theoretical calculations,
Zhou and coworkers found that the size of graphenedetermines its elec-
tron afﬁnity (EA) values. Theoretical calculations indicated that the size
of a graphene sheet correlates with its ability to accept electrons.
Graphene sheets with diameters greater than 6.7 nm are stronger elec-
tron acceptors than 4Fe4S iron–sulfur clusters, the reduction of which
may be inhibited by these larger graphene sheets. The turning points
at which graphene becomes an inhibitor of the reduction of Fe-
porphyrin, 2Fe2S, and 3Fe4S are 1.2 nm, 2.9 nm, and 5.6 nm, respective-
ly. The results of ESR indicated that nano-sized graphene alters the elec-
tronic distribution state, which may be due to the inhibitory effects of
graphene on the reduction of three-valent iron ions to two-valent iron
ions via the disruption of electron transfer [56]. Bypassing the electron
transport chain by graphene impairs not only ATP production but also
ROS overproduction.
Although size of the GO sheet plays a role, the functional group den-
sity on the GO sheet is one of the key components in ROS generation.
Das and coworkers systematically investigated the toxicity of GO and
rGO using an in vitro cell culture model system. They found GO is
more toxic than rGO of same size. GO and rGO induce signiﬁcant in-
creases in both intercellular ROS levels and mRNA levels of HO1 and
TrxR, two key genes involved in redox signaling. Such observations sup-
port the hypothesis that oxidative stressmediates the cellular toxicity of
GO. Oxidative stress-induced cytotoxicity reduces with a decreasing ex-
tent of oxygen functional group density on the rGO surface, suggesting
that it is possible to minimize the toxicity of GO and unravel its wide
range of biomedical applications by controlling the GO reduction and
maintaining the solubility [67].
Mitochondria are regarded as the major source of ROS generation;
however, other cellular components are also involved. Horváth and co-
workers evaluated the toxicity of GO and rGO in A549 human lung can-
cer cells and RAW 264.7 macrophages and found that cells treated with
0.0125–12.5 μg/cm2 of GO or rGO for 5 days showed a dose-dependent
cytotoxicity, whichwas due to the generation of ROS via the interaction
of the nanomaterial with the cell surface during the initial phase of the
exposure [40].
4.2.3. Remodeling of cellular energy metabolism
Cell survival and growth depend on metabolic pathways that pro-
duce energy, precursors for macromolecular synthesis, and substrates
for other essential cellular functions. However, when cells face a consid-
erable metabolic challenge, they may drastically adjust their utilization
of many different metabolic pathways. For example, normal cells show
activemitochondrial respiratory function and use oxidative phosphory-
lation (OXPHOS) as the main route to generate ATP. By contrast, cancer
cells often exhibit an increased rate of glycolysis even in the presence of
high O2 concentrations. This phenomenon of “active aerobic glycolysis”
is known as the Warburg effect, which is regarded as an important
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inhibited mitochondrial OXPHOS in breast cancer cell lines. More
importantly, GO had no apparent effect on the mitochondrial OXPHOS
in non-cancerous mammary epithelial cells. Unlike OXPHOS, glycolysis
in breast cancer cells was not affected by GO exposure and thus can
partially compensate for the impaired OXPHOS in order to maintain es-
sential ATP production [33]. Hu and coworkers investigated the impact
of GO on the cellular metabolic proﬁles. A metabolomics analysis re-
vealed signiﬁcant differences between the control and GO-treated
cells: the metabolisms of alkanes, lysine, octadecadienoic acid, and
valine were associated with GO-induced ROS production and could be
considered as new biomarkers of ROS. These authors also suggested
that the GO-induced cytotoxicity involved the inhibition of fatty acid,
amino acid, and small molecule acid metabolisms [61].
To explore themechanismunderlying alterations to cellmetabolism,
Zhou and coworkers analyzed the effects of GO on protein expression.
By using a SILAC-based quantitative proteomics approach, they found
that GO down-regulated the expression of multiple mitochondrial
OXPHOS-related proteins, including NDUFA8, NDUFA9 (Complex I),
SDHB (Complex II), UQCRC2 (Complex III), COX2, COX4I1 (Complex
IV), ATP5C1, ATP5F1 (Complex V), and multiple enzymes involved in
the TCA cycle, in breast cancer cells but not in non-cancerous cells.
Therefore, they hypothesized that GO remodels the metabolisms
of breast cancer cell lines by regulating pathways involved in energy
metabolism [33].4.3. Impact on other cellular components
Jin and coworkers reported that GO could enter A549 lung cancer
cells and located within the cytoplasm and nucleus [68]. Similar results
were also obtained in human dermal ﬁbroblasts (HDF) [69]. Based on
this cytoplasm-nucleus shuttle effect, graphene-derived nanomaterials
might be used as carriers for drugs and genes. Wang and coworkers re-
ported that graphene quantum dots (GQDs) could efﬁciently deliver
doxorubicin (DOX) to the nucleus through DOX/GQD conjugates,
which could increase the nuclear uptake of DOX, and thus enhance
the cytotoxicity of DOX in drug-resistant cancer cells [70]. Chen and
coworkers also reported that cis-diaminedichloroplatinum (CDDP)
conjugated with GO could induce the nuclear import of CDDP effective-
ly. In this process, importin-alpha/beta may play a critical role in theCo
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stained with Alexa-Fluor 488-labeled phalloidin for F-actin (green), an antibody against cortac
were quantiﬁed as a percentage of the cell circumference on 50 randomly selected cells in each
with permission, copyright © Elsevier B.V. 2014.nuclear import of CDDP [71]. Probably these conjugates assume differ-
ent cellular and nuclear internalization pathways comparing to free
drugs.
Cytoskeleton is another key cellular component interacts with
graphene and graphene-related nanomaterials. Matesanz and co-
workers reported that GO nanosheets are localized on F-actin ﬁlaments
of Saos-2 osteoblasts after their internalization, and thus impact cell
cycle and cell death via a cytoskeleton-dependent manner [50]. Zhou
and coworkers observed the impact of GO on the dynamics of cytoskel-
eton assembly in metastatic MDA-MB-231 breast cancer cells, and
found that expose to GO leads to the disruption of F-actin cytoskeletal
assembly within the lamellipodia and thus impaired cell migration
(Fig. 6). By analyzing the expression of cytoskeleton-related genes,
they found that two small GTPases involved in F-actin cytoskeleton
assembly, Rac1 and RhoA, were down-regulated in MDA-MB-231 cells
upon PEG-GO exposure [56]. Thus, graphene and graphene-related
nanomaterials might inﬂuence the cytoskeleton via both direct and
indirect mechanisms. Overall, these combined data delineated the
molecular mechanisms underlying the in vivo and in vitro biological
behaviors of graphene.
5. Biological effects of graphene on certain types of cells
The applications of graphene in biomedical ﬁelds have prompted
substantial interest. Graphene substances that are usually functional-
ized have been designed to target different types of cells, including
hemocytes, endothelial cells, phagocytes, and cancer cells. Therefore, it
is essential to understand the interactions between graphene and
these particular types of cells.
5.1. Biological effects on cells of the circulatory system
Graphene and graphene-related nanomaterials may enter the
bloodstream and interact with blood components following their ad-
ministration intended for biomedical purposes. The surface chemistry
determines the hemocompatibility of graphene. For example, GO sheets
elicited strong aggregatory response in platelets, while rGO was signiﬁ-
cantly less effective in aggregating platelets [72]. Once introduced into
systemic circulation, graphene encounters various biomolecules and
interacts with the cells of the circulatory system. This interaction alterserge Zoom
MDA-MB-231
Control G40  G80
0
10
20
30
40
* *
La
m
el
lip
od
ia
 
ex
te
n
t
(%
 
o
f c
el
l c
irc
u
m
fe
re
n
ce
)
B
B-231 cellswere seeded on cover slips, exposed to 40 or 80 μg/ml PEG-GO for 24h and then
tin (red) and DAPI for nuclei (blue). Scale bar, 5 μm. (B) Lamellipodia extents at cell edges
group. Values represent the means ± SEM, *p b 0.05. Image adapted from reference [33]
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of graphene.
5.1.1. Formation of the protein corona
It has been well established that when nanomaterials interact with
biological systems, biomolecules, particularly proteins, attach to their
surfaces to forma complex between the nanoparticle surface and the pro-
teins called corona. The protein corona is a key concept in nanomedicine
and nanotoxicology because it provides a biomolecular identity for
nanomaterials in a biological environment. Thus, the interaction of a
biological system with a nanomaterial depends on the composition of
the protein layer rather than the surface characteristics of the
nanomaterial itself. However, understanding the protein–graphene
interaction of the corona and its inﬂuence on cellular responses is a
challenging task at the nano-bio interface [73].
The bloodstream contains abundant protein molecules. Graphene
can spontaneously and rapidly interact with a wide range of proteins,
leading to signiﬁcant changes in the size, zeta potential, andmorpholo-
gy of the graphene particle [74]. Using simulation-based (molecular
dynamics) approaches, Chong and coworkers demonstrated that theFig. 7. Formation of the protein corona improves the biocompatibility. (A) Protein corona-med
FBS-coatedGOnanosheets (100 μg/ml) at 37 °C for 2 h. The ultrastructure of cells were observed
the induction of cell death. However, no apparent morphological alterations were observed in
GO. (B) The quantiﬁcation of FBS on cytotoxicity of GO nanosheets. (B-a) Cell viability of A549
containing various concentrations of FBS for 2 h. (B-b) Cell viability of A549 cells treatedwithGO
corona human plasma proteins following incubation at different plasma concentrations [81]. I
Society 2011 & Elsevier B.V. 2013.adsorption of four highly abundant blood proteins onto GO and rGO
was mainly enthalpically driven through strong π−π stacking interac-
tions between the aromatic rings of the proteins and the graphene
sp2-carbons, although hydrophobic interactions also occurred [75].
However, basic residues such as arginine also play an equally important,
or even more important, role during this process. The strong dispersion
interactions between the side chains of these solvent-exposed basic
residues and the graphene surface provide the driving force for a tight
binding between these basic residues and graphene [76]. Graphene–
protein interactions depend on the types of the proteins within the mi-
croenvironment. Ultimately, the decoration of the corona (i.e., the type,
amount, and conformation of the attached proteins) can determine the
biological fate of graphene [77]. On the other hand, Tenzer and co-
workers show that various size and surface functionalization of nanopar-
ticles could adsorb different proﬁles of human plasma coronas by assay
of label-free snapshot proteomics [78]. Xu and coworkers prepared a se-
ries of GO derivatives, including aminated GO (GO-NH2), poly(acryl-
amide)-functionalized GO (GO-PAM), poly(acrylic acid)-functionalized
GO (GO-PAA), and poly(ethylene glycol)-functionalized GO (GO-PEG),
and compared their toxicity with pristine GO. They hypothesized thatiated mitigation of cytotoxicity of graphene oxide. A549 cells were with GO nanosheets or
with TEM. GO exposure caused cell shrinkage and fragmentation in A549 cells, suggesting
cells exposed to FBS-coated GO, indicating that protein corona mitigate the cytotoxicity of
cells treated with GO nanosheets (20 μg/ml, 100 μg/ml) dispersed in RPMI medium 1640
(10% FBS) and FBS-coatedGOnanosheets for 4 and6 h [80]. (C) SDS–PAGEanalysis of hard
mage adapted from References [80,81] with permission, copyright © American Chemical
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compositions of protein corona, especially immunoglobulin G (IgG).
They deciphered the different components in protein corona, which
determined the adsorption onto membrane and cellular uptake. It
could be discerned that the proﬁles for each GO material were quite
different, indicating the protein corona on various GO sheets was distinct,
presumably due to their different size, surface charge (reﬂected by their
zeta potential values), and hydrophobicity [49].
5.1.2. Formation of the protein corona improves the hemocompatibility
Nano-sized GO induces severe hemolysis in vitro; however, a proper
surface coating can remarkably improve its hemocompatibility [79,80].
Hu and coworkers investigated the interactions between GO and serum
proteins systematically. They found that upon serum exposure, the
thickness of GO substantially increased to the range 4.0–18.0 nm from
a thickness of 1.0 nm, suggesting that a large amount of proteins had
coated the surfaces of the GO nanosheets (designated as FBS-coated
GO). More importantly, they found that the formation of the serum
albumin-based protein corona could mitigate the cytotoxicity of GO
nanosheets. This may be due to the prevention of GO-induced physicalFig. 8. Signaling pathway ofmacrophage activation stimulated by graphene nanosheets. Graphe
dependent mechanism. Activation of IKK initiates the phosphorylation and consequent degra
nucleus. NF-κB binds to the promoter regions of its effector genes and initiates the transcrip
factors, including IL-1α, IL-6, IL-10, TNF-α, CM-CSF, MCP-1, MIP-1α, MIP-1β, and RANT
macrophages. Image adapted from Reference [89] with permission, copyright © Elsevier B.V. 2damage to the cellmembrane (Fig. 7A, B) [80].Mao and coworkers com-
pared the composition of protein coronas and found that by increasing
the human plasma concentration, the afﬁnity of low-molecular-weight
proteins to the surfaces of graphene sheets is signiﬁcantly increased
(Fig. 7C) [81].
Cheng and coworkers reported that reduced graphene oxide (rGO)
with corona composedwith biopolymer functionalization havemarked-
ly elevated biocompatibility, which exhibit an ultra-low hemolysis ratio
(lower than 1.8%) in human blood cells and has good cytocompatibility
for human umbilical vein endothelial cells (HUVEC) even at a high con-
centration of 100 μg/ml [82]. Similar results have been obtained from
other graphene derivatives. Papi and coworkers reported recently that
after interacting with plasma proteins, nano-sized GO ﬂakes, which
can disrupt the erythrocyte plasma membrane, had greatly reduced
hemolytic activities [83]. Mbeh and coworkers also reported that the
preincubation of graphene-oxide nanoribbon (GONR; a relatively ho-
mogenous graphene-related nanomaterial synthesized using oxidative
unzipping of multi-walled carbon nanotubes) with human plasma
serum (HPS), leading to the formation of a protein corona on the surface
of the GO nanoribbons, decreased the cytotoxicity markedly in HUVECnemaybe recognizedby certain types of TLRs, thus activating kinase cascades via aMyD88-
dation of IκB, resulting in the release of NF-κB subunits, and their translocation into the
tion of multiple proinﬂammatory genes and the secretion of various proinﬂammatory
ES. These proinﬂammatory factors modulate the immune responses of neighboring
012.
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between graphene and biomoleculesmay provide an alternative and con-
venient route to enhancing the biocompatibility of graphene/biomolecule
complexes through functional modiﬁcation; these complexes could then
be used for safe biomedical applications.
5.1.3. Potential medical applications based on graphene–protein interactions
Hajipour and coworkers developed “personalized protein coronas” by
decorating GO sheets with plasma from human subjects with different
diseases/conditions, including hypoﬁbrinogenemia, leukemia, thalasse-
mia, rheumatism, fauvism, hypercholesterolemia, diabetes, and pregnan-
cy. These “personalized protein coronas” triggered different biological
responses and exhibited signiﬁcantly different properties in terms of cel-
lular toxicity, apoptosis, cellular uptake, reactive oxygen species produc-
tion, lipid peroxidation, and nitrogen oxide levels, which could help
researchers to design efﬁcient, safe, and patient-speciﬁc nanobiomaterials
in a disease type-speciﬁc manner for clinical and biological applications
[85]. The interaction between graphene and proteins also inﬂuences the
biological functions of the proteins. Yang and coworkers reported
that graphene can destroy amyloid ﬁbrils through the penetration and
extraction of peptides, which may be of potential use in the therapy of
Alzheimer's disease [86].
5.2. Biological effects on macrophages
Recently, an increasing number of studies have focused on the inter-
actions between graphene and immune cells; the majority of these
works have been carried out in macrophages [87]. Macrophages, which
differentiate from circulatingmonocytes, are key innate immune effector
cells best known for their role as professional phagocytes. Macrophages
have proteolytic and catabolic activities and ingest pathogens through
phagocytosis, by scavenging cellular and exogenous debris, and by re-
modeling tissues after injury. These cells are also pivotal in the uptake
of nanoparticles. Intravenously injected graphene-based nanomaterials
are likely to be cleared out by macrophages before reaching their target
sites. Graphene derivatives stimulate the activation of macrophages,Fig. 9. Potential application of graphene in stem cell therapy. Reduced graphene oxide (rGO) sh
intomesenchymal stem cells (MSC) spheroids, it is possible to enhance the cell–ECM interaction
from Reference [101] with permission, copyright © JohnWiley & Sons Inc. 2015.thereby triggering the production and release of cytokines/chemokines
that mediate the inﬂammatory responses.
5.2.1. Uptake of graphene by macrophages
Unlike non-phagocytic cells, macrophages uptake graphene effective-
ly via phagocytosis that has already been explored. Yue and coworkers in-
vestigated the uptake of 2 μmand350nmGOparticles in three cancer cell
lines, andHUVECendothelial cells,ﬁnding that theGO internalizationwas
negligible in all of these non-phagocytes [88]. They suggested this might
be due to strong electrostatic repulsions between GO particles and the
negatively charged cell surface. In contrast to the low GO signal found in
non-phagocytic cells, obvious increases in GO ﬂorescence were detected
in primary murine macrophages and J774A.1 macrophages, suggesting
that macrophages are highly capable of GO uptake. Moreover, active
phagocytosis may be powerful enough to overcome the electrostatic re-
pulsion barrier that exists in the macrophage–GO interaction. These
authors further analyzed the detailed internalization behavior of GO in
primary macrophages by selective inhibition of certain phagocytosis re-
ceptors, ﬁnding a signiﬁcant reduction in uptake after the Fcγ receptor
was blocked with IgG antibody. This result revealed a key role for the
FcγR-mediated phagocytic pathway in GO entry.
Zhou and coworkers investigated the interaction between pristine
graphene and macrophages. By combining confocal microscopy and
live cell imaging, they dissected the molecular mechanisms by which
graphene is internalized. They found that the ability of primary macro-
phages to uptake graphene is abolished by knockout of the MyD88
adaptor protein, suggesting the essential role of toll-like receptors
(TLR) in the phagocytosis of pristine graphene [89].
5.2.2. Initiation of proinﬂammatory signaling pathways
After its phagocytosis by macrophages, graphene may initiate a
cascade of events leading to inﬂammatory responses, which are charac-
terized by the production and secretion of proinﬂammatory cytokines
and chemokines. Yue and coworkers compared the effects of 2 μm and
350 nm GO particles on the production of interleukin-6 (IL-6), IL-10,
IL-12, tumor necrosis factor (TNF)-α (TNF-α), monocyte chemotactic
protein-1 (MCP-1), and interferon-γ (IFN-γ) in macrophages and foundows high afﬁnity toward extracellular matrix (ECM) proteins. By incorporating rGO ﬂakes
s and improve the therapeutic efﬁcacy ofMSCs for ischemic heart diseases. Image adapted
Table 1
Interactions between graphene-related nanomaterials and cells.
Material Size Functionalization Cell types Exposure conditions Effects References
Pristine graphene Thickness: 2–3 nm;
diameter: 172.7 ± 75.6 nm
– Peritoneal macrophages;
RAW264.7 cells
20 μg/mL for 24 h The interaction of murine macrophages with pristine graphene results
in elevated transcription and secretion of cytokines and chemokines,
which is triggered by activation of the NF-κB signaling pathway
[89]
Pristine graphene Thickness: 2–3 nm;
size: 500–1000 nm
– RAW 264.7 0–80 μg/mL for 24 or 48 h Induction of cytotoxicity through the depletion of the mitochondrial
membrane potential and the increase of intracellular reactive oxygen
species, then trigger apoptosis by activation of themitochondrial pathway.
[58]
Pristine graphene;
functionalized graphene
Thickness: ~0.4 nm Carboxylated RAW 264.7 75 μg/mL for 24 h or 48 h Macrophages showed relatively high intracellular uptake of
functionalized, hydrophilic graphene compared to the hydrophobic
pristine graphene.
[94]
Graphene; few layer
graphene (FLG)
microsheets
Lateral dimension: 0.5–10 μm;
layer numbers: 4–25
– Primary human
keratinocytes;
Human lung epithelial
cells;
Murine macrophages
5 h (macrophages)24 h
(other cell types);
Graphene-related nanomaterials enter cells through spontaneous
membrane penetration at edge asperities and corner sites
[44]
Graphene Average grain size: ~10 μm – HeLa;
Panc-1
– The cellular responses to the graphene sheets are strongly dependent
to either cell type or hard corona composition.
[81]
Graphene quantum dots
(GQDs)
1.5–5.5 nm – THP-1 0–200 μg/mL, for 24, 48 or
72 h
GQDs induce inﬂammatory response, apoptosis, and autophagy in
macrophages via p38 MAPK and NF-κB signaling pathways.
[60]
Pluronic dispersed
graphene; GO
– – Lung cells administered directly into
the lungs of mice
Graphene-related nanomaterials increased the rate of mitochondrial
respiration and the generation of reactive oxygen species, activating
inﬂammatory and apoptotic pathways
[63]
Graphene, GO Thickness: 3–4 nm;
diameter: 100–200 nm
– MDA-MB-231;
B16F10;
PC3
20 μg/ml; 24 h Graphene or GO inhibits the migration and invasion of various cancer
cells by inhibiting the activities of ETC complexes
[56]
Carboxyl graphene
nanoplatelets (CXYG)
– – HepG2 0–32 μg/mL for 72 h CXYG nanoplatelets caused cytotoxicity in HepG2 cells with plasma
membrane damage and induction of oxidative stress
[48]
GO Thickness: 6 nm;
lateral size: 40 nm
– HepG2 1–200 mg/L for 24 h NADPH oxidase dependent ROS formation; deregulation of
antioxidant/DNA repair/apoptosis related genes
[32]
GO Thickness: ∼1.0 nm;
average size: 51 nm
– GLC-82 100 mg/L for 48 h Alters the miRNA expression proﬁle [34]
GO 385 nm – HepG2 0–16 μg/mL for 72 h GO caused cytotoxicity in Hep G2 cells with plasma membrane damage
and induction of oxidative stress
[48]
GO Thickness: ~1.8 nm;
size: 10–120 nm
PEG RAW-264.7;
Saos-2;
3T3
– Impact on cytoskeleton; alterations in cell cycle [50]
GO and its nanoassemblies Size: 100–200 nm;
thickness: 5–10 nm
layer-by-layer (LbL)
assembly
Mouse embryonic
ﬁbroblast (MEF)
l μg/mL;
24–72 h
Without induction of noticeable harmful effects [53]
GO, bGO, pGO-5, pGO-30,
and GS
Hydrodynamic diameter in
PBS:
GO: 1678 ± 190 nm;
bGO: 1574 ± 160 nm;
pGO-5: 1254 ± 143 nm;
pGO-30: 861 ± 115 nm;
GS: 4312 ± 206 nm
– Red blood cells;
Human skin ﬁbroblasts
0–200 μg/mL, for 3 h or 24 h All the GO and GS show dose-dependent hemolytic activity on RBCs.
Sonicated (smaller) GO exhibited higher hemolytic activity than
untreated (larger) GO. Compared to individually dispersed GO sheets
having higher surface oxygen content, the aggregated GS showed
lower hemolytic activity.
[45]
GO Thickness: 1.2 nm;
average size: 200–260 nm
– MEF 50 μg/mL for 24 h As the oxidation degree decreased, GO derivatives led to a higher
degree of cytotoxicity and apoptosis.
[65]
GO Thickness: ~1 nm;
lateral length: 0.2–1 μm
– Human ﬁbroblast cell 0–100 μg/mL 0–5 days GO could produce cytotoxicity in dose- and time-dependent means,
and can enter into cytoplasm and nucleus, decreasing cell adhesion,
inducing cell ﬂoating and apoptosis.
[69]
GO Thickness of GO: 0.9 nm;
thickness of GO with protein
corona: 5–10 nm
protein corona Red blood cells – GO ﬂakes have a very strong hemolytic activity increasing with the GO
ﬂakes size reduction. This activity was almost absent when the plasma
protein corona was absorbed on the GO ﬂakes surfaces.
[83]
GO Thickness of GO-FBS:
4.0–18.0 nm
10% FBS A549 20–100 μg/mL for 0–12 h The cytotoxicity of GO is largely attenuated when GO is incubated with
FBS, which is due to the extremely high protein adsorption ability of GO.
[80]
GO – – Peritoneal macrophage;
J774A.1;
0–20 μg/mL The GO in micro-size induced much stronger inﬂammation responses
while nano-sized graphene sheet showed better biocompatibility
[88]
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LLC;
MCF-7;
HepG2;
Human umbilical vein
endothelial cells (HUVEC)
GO Large GO: 2.4 μm
Small GO: 350 nm
– RAW264.7 5–100 μg/mL for 24 h. GO treatment provoked the toll-like receptor (TLR) signaling cascades and
triggered ensuing cytokine responses
[90]
GO Thickness: 1 nm
size: 1–2 μm
aminated; carboxylated J774A.1;
RAW 264.7
20 μg/mL for 24 h Interaction of GO with TLR4 results in activation of TLR4 signaling, which
is the predominant molecular basis for GO-mediated macrophagic
necrosis.
[91]
GO Large: 1.32 μm
small: 0.27 μm
very small: 0.13 μm
– Human monocyte derived
macrophages;
Peritoneal macrophages
1–100 μg/mL for 24 h GO sheet size had a signiﬁcant impact on different cellular parameters
(i.e. cellular viability, ROS generation, and cellular activation). The
more the lateral dimensions of GO were reduced, the higher were the
cellular internalization
[93]
GO, PVP-GO Thickness of GO: 1.7 nm
thickness of PVP-GO: 2.5 nm
PVP Dendritic cells 25–100 μg/mL for 48 h PVP-modiﬁed GO has a low immunogenicity than unadorned GO [95]
GO, TiO2-GO diameter: 300 nm – A549 100 and 300 μg/ml for 4 h GO enter A549 cells and located in the cytoplasm and nucleus without
causing any cell damage. The TiO2-GO composite separated into GO and
TiO2 after TiO2-GO composite entered A549 cells
[68]
GO, sGO GO: 0.5–3 μm
sGO: b15 nm
– PC-12 12.5 μg/mL for 48 h. Inhibit Aβ peptide monomer ﬁbrillation and clear mature amyloid
ﬁbrils
[86]
GO Flake thickness: ∼1.5 nm
size: 1–6 μm
– Mesenchymal stem cells
(MSC)
10 μg/mL GO ﬂakes effectively prevent a series of adverse cell-signaling cascades
that result in the anoikis of MSCs in response to ROS
[102]
GO GO: 80 nm
PEG-GO: 100 nm
PEG; labeled with FITC Saos-2;
HepG2;
RAW-264.7
37.5 μg/mL FITC-PEG-GOs
for 2 h
Several processes are involved in FITC-PEG-GOs uptake, including
micropinocytosis, microtubule-dependent mechanisms,
clathrin-dependent mechanisms, and phagocytosis
[36]
GO Thickness: 1.1 nm;
diameter: 0.84 ± 0.41 μm,
FITC-BSA C2C12 20–50 μg/mL for 30
min–14 h
Small nanosheets enter cells mainly through clathrin-mediated
endocytosis, and the increase of graphene size enhances phagocytotic
uptake of the nanosheets.
[37]
GO thickness: 2–3 nm
lateral length: 100–200 nm
PEG MDA-MB-231;
MDA-MB-436;
SK-BR-3
40 or 80 μg/ml for 24 h PEG-GO inhibited the migratory and invasive properties of human
metastatic breast cancer cell lines by inhibiting ATP synthesis, leading
to a disruption of F-actin cytoskeletal assembly
[33]
NGO Size: 5–50 nm PEG HCT-116 No apparent toxicity as drug carrier [79]
NGO Thickness: 1.4 nm;
diameter: 20–40 nm
PEG-Ce6
PEG-BPEI-Ce6
HeLa – No apparent toxicity as drug carrier [57]
Oxidized graphene
nanoribbons (O-GNR)
width: 125–220 nm;
lengths: 500–2500 nm
PEG-DSPE HeLa;
NIH-3T3;
SKBR3;
MCF7
10–400 μg/mL for 12–48 h O-GNR-PEG-DSPEs show a dose-dependent and time-dependent
cytotoxic effects on the four cell lines.
[39]
O-GNR – PEG-DSPE MCF7;
A549;
MRC5
50 μg/mL for 30 min Signiﬁcant O-GNR-PEG-DSPE uptake into cells with high EGFR expression. [42]
O-GNR Average widths: 100–300 nm
length: 500–2500 nm
PEG-DSPE U251;
CG-4;
MCF-7
– No apparent toxicity as drug carrier [43]
O-GNR Thickness: ∼1.0 nm
widths: ∼100 nm
albumin A549 0–100 μg/mL for 24 h The protein-functionalized GONRs with concentrations ≤50 μg/mL
showed no signiﬁcant cytotoxicity on the cells. However, the high
concentration of 100 μg/mL exhibited signiﬁcant cytotoxicity resulted
in decrease of cell growth and induction of cell apoptosis.
[84]
O-GNR, GNO, and GONP O-GNR: (w)x(l) 60–90 nm ×
500–1500 nm
GNO: (d) 50–300 nm
GONP: (d) 20–40 nm
DSPE-PEG MSC 0–300 μg/mL
24–72 h
GNOs, GONRs, and GONPs at concentrations of less than 50 μg/ml for 24
or 72 h could be considered potentially safe incubation conditions for
ex vivo labeling for MSCs.
[41]
GO; rGO GO, lateral dimension:
0.5–3 μm;
rGO, lateral dimension:
0.5–3 μm
blood proteins (bovine
ﬁbrinogen,
immunoglobulin,
transferrin, and bovine
serum albumin)
A549 200 μg/mL
24 h
Protein-coated graphene resulted in a markedly less cytotoxicity than
uncoated graphene
[75]
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Table 1 (continued)
Material Size Functionalization Cell types Exposure conditions Effects References
GO, rGO Thickness of: ~1 nm;
Size: 0.4–0.8 μm
– HUVEC 10 μg/mL GO is found to be more toxic than rGO of same size. GO and RGO induce
signiﬁcant increases in both intercellular ROS levels and mRNA levels of
HO1 and TrxR. Moreover, a signiﬁcant amount of DNA damage is
observed in GO-treated cells, but not in RGO-treated cells. Oxidative
stress-induced cytotoxicity reduces with a decreasing extent of oxygen
functional group density on the rGO surface.
[67]
GO, rGO – A549;
RAW 264.7
0.0125–12.5 μg/cm2 for 5
days
Cells treated with lower concentrations of GO/rGO did not lead to
increases in ROS production. Cellular internalization of GO was observed
in phagoendosomes without signs of any intracellular damage.
[40]
rGO/HArGO ~100 nm ICG-loaded KB 20 μg/ml for 24 h No signiﬁcant cell death observed in the absence of NIR irradiation [15]
rGO ~150 nm PNT-anchored Ramos;
CCRF-CEM
– No apparent toxicity as drug carrier [23]
rGO thickness: 7 nm
lateral size: 40 nm
– HepG2 1–200 mg/L for 24 h hydrophobic rGO was found to mostly adsorbed at cell surface without
internalization, ROS generation by physical interaction, poor gene
regulation
[32]
rGO – biopolymer functionalized Human blood cells;
HUVEC
1–100 μg/mL 24 h The biocompatible biopolymer functionalized RGO exhibited excellent
biocompatibility
[82]
rGO, GONP, rGONP, – – MSC 0.01–100 μg/mL for 24 h The rGONPs exhibited a strong potential in destruction of the cells with
the threshold concentration of 1.0 mg/mL, while the cytotoxicity of the
rGO sheets appeared at high concentration of 100 mg/mL after 1 h. The
results indicated that interaction of graphene derivatives with stem
cells strongly depends on the lateral size of the sheets.
[51]
GO, rGO Thickness: 1 nm;
size: 0.4–0.8 μm;
– HUVEC 1–10 μg/mL for 24 or 48 h GO exhibits higher toxicity than rGO due to ROS generation. Small ﬂake
size graphene exhibit greater cytotoxicity compared to larger sheets
due to intracellular accumulation of graphene.
[67]
GO, rGO Size: 0.2–5 μm – Human platelets 0–20 μg/mL GO can evoke strong aggregatory response in platelets comparable to
that elicited by thrombin.
[72]
GO, rGO, G-NH2 Size: 2 μm Amine-modiﬁed Red blood cells 2–10 μg/mL for 3 h G-NH2 is not endowed with thrombotoxic property. [103]
GO, rGO GO: 100 nm to 10 μm
rGO: 100 nm to 1.5 μm
– U87
U118
100 μg/mL GO and rGO enter glioma cells and have different cytotoxicity. Both
types of platelets reduced cell viability and proliferation with
increasing doses, but rGO was more toxic than GO. Moreover, the level
of apoptotic markers increased in rGO-treated tumors. rGO induces cell
death mostly through apoptosis.
[104]
rGO Size: 100 nm−1.5 μm. Arg, Pro U87 50 μg/mL Reduction in GBM tumor volume was observed. rGO + Arg shows
anti-angiogenic and pro-apoptotic characteristics.
[105]
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159B. Zhang et al. / Advanced Drug Delivery Reviews 105 (2016) 145–162that the secretion of inﬂammatory cytokines was highly dependent on
the GO dosage, particularly for the 2 μm GO particles [88]. Zhou and co-
workers demonstrated the biological effects of sub-cytotoxic concentra-
tions of pristine graphene on both primary murine macrophages and
immortalized macrophages. They reported that graphene signiﬁcantly
stimulates the secretion of Th1/Th2 cytokines, including IL-1α, IL-6,
IL-10, TNF-α, and granulocyte macrophage colony-stimulating factor
(GM-CSF), as well as chemokines, includingMCP-1, macrophage inﬂam-
matory protein-1α (MIP-1α), MIP-1β, and regulated on activation,
normal T Cell expressed and secreted (RANTES), probably by activating
TLR-mediated and NF-κB-dependent transcription (Fig. 8) [89]. Li and
coworkers reported that pristine graphene activated both the MAPK
and transforming growth factor-β (TGF-β)-related signaling pathways
in macrophages [58]. Chen and coworkers reported that GO treatment
of macrophages activated the TLR signaling cascades. TLR4 and TLR9
and their downstream signaling mediators MyD88, TRAF6, and NF-κB
were also found to play pivotal roles in the GO-induced inﬂammatory
responses [90].
5.2.3. Graphene-induced inﬂammation responses
The initiation of proinﬂammatory signaling and the production of
proinﬂammatory cytokines and chemokines cause signiﬁcant biological
effects on bothmacrophages and neighboring cells. By using a coculture
system, Zhou and coworkers exposed naïve macrophages to factors
secreted by graphene-exposed macrophages, ﬁnding that the factors
altered the morphology of naïve macrophages by remodeling their
actin assembly, and, as a result, markedly decreased their ability to
adhere to the extracellular matrix. The ability of these cells to undergo
phagocytosis was also attenuated. Based on this evidence, these authors
suggested that in graphene-exposed macrophages, the immune re-
sponse underwent negative feedback. Moreover, they hypothesized
that the graphene-induced factors may play an important role in the
prevention of over-activation after graphene exposure [89]. However,
when macrophages are exposed to high concentrations of graphene,
they might undergo different types of cell death. Li and coworkers
reported that pristine graphene activated Bim and Bax, two pro-
apoptotic member of the Bcl-2 protein family, via the MAPK and TGF-β
signaling pathways in macrophages. Consequently, caspase 3 and its
downstream effector proteins, such as PARP, were activated, resulting
in the execution of apoptosis [58]. Graphene also induced autophagy in
macrophages [90]. Qu and coworkers demonstrated that GO induced
necrotic cell death in macrophages, which is mediated by activation of
TLR4 signaling and subsequently by TNF-α production [91].
5.2.4. Control of graphene-induced inﬂammation
Macrophage-initiated inﬂammation contributes to graphene-induced
tissue damage in vivo. GO exposure has been shown to cause severe lung
inﬂammation in mice, which is accompanied by bronchoalveolar lavage
ﬂuid pleocytosis, which consists of the leakage of protein into the alveolar
space, and elevated levels of proinﬂammatory cytokines [63].
Graphene-induced inﬂammation responses could be regulated by
different approaches, including controlling the size and thickness of
the graphene sheet and surfacemodiﬁcation. Bussy and coworkers con-
sidered the key physicochemical characteristics (the structure, surface,
and colloidal properties) of graphene at the cellular, tissue, and whole
body physiological levels, summarizing the evidence for health effects
at all three levels. They offered a set of rules for the development of
graphene and its derivatives to enhance the overall safety andminimize
the risks for adverse reactions in humans due to graphene exposure. For
instance, they recommended the use of small, individual graphene
sheets that can be efﬁciently internalized bymacrophages and removed
from the site of deposition [92]. It should be noted that the GO sheet size
has a signiﬁcant impact on the different parameters of macrophages
(i.e., cellular viability, cellular activation, and ROS generation) [93].
Compared with 2 μm-sized GO, 350 nm-sized GO only triggeredmoderate proinﬂammatory cytokine production in vitro and mediated
slight inﬂammation cell inﬁltration in vivo [88].
Surface modiﬁcation also inﬂuences the interaction between
graphene and macrophages. Sasidharan and coworkers tested both
pristine and functionalized graphene for their interactions with murine
macrophages, ﬁnding that the toxicity of hydrophobic pristine samples
could be signiﬁcantly reduced by surface functionalization [94]. The en-
hanced biocompatibility of graphene by surface modiﬁcation was also
observed in other cell types of the immune system, including dendritic
cells (DCs) and T lymphocytes [95].
The interaction of graphene with the immune system is still at a very
early stage of investigation. This comprehensive investigationwill provide
a useful compass to guide future research in biomedicine. Understanding
and controlling the interaction of graphene-based materials with macro-
phages is key to the development of graphene-enabled biomedical tech-
nologies and to the management of graphene health and safety issues
[96].
5.3. Biological effects on cancer cells
Numerous nanomaterials such as liposomes, polymers/dendrimers,
metal nanostructures, and carbon nanostructures are used to selectively
target drugs to tumors. Among them, nanomaterials fabricated using
graphene have drawn considerable attention for use in biomedical appli-
cations due to their unique physical and chemical properties. The large
surface area of carbon-based nanomaterials has made them good drug
carrier candidates. However, unmodiﬁed pristine graphene tends to
form aggregates due to its hydrophobic nature, which limits its biomed-
ical application. In 2008, Liu and coworkers overcame the aggregation
issue of graphene by using a more hydrophilic derivative of graphene,
PEGylated GO. They used the GO nanosheet for the intracellular delivery
of water-insoluble anticancer agents and obtained signiﬁcant tumor
suppression effects in vitro and in vivo [79]. Since then, the application
of GO as an effective drug nanocarrier has sparked growing interests in
the biomedical ﬁeld for cancer therapy [97]. Graphene derivatives could
also be used as photothermal therapeutic agents [98] and imaging agents
in cancer research due to their photo and thermal characteristics. For
example, silver-embedded nanoparticles deposited onto doxorubicin-
coupled GO exhibit very high drug-loading efﬁciency, impart excellent
chemo-photothermal therapeutic efﬁcacy, tumor targeting, and laser-
controlled drug release, and aid in enhancing X-ray imaging [99].
Functionalized graphene can act as efﬁcient anticancer nanoplatform
[26], whereas graphene itself shows tumor suppression effects in vitro
and in vivo. Zhou and coworkers reported that low concentrations of
pristine graphene and GO show no apparent inﬂuence on the viability
of MDA-MB-231 human breast cancer cells, PC3 human prostate cancer
cells, or B16F10mousemelanoma cells. However, bothpristine graphene
and GO can effectively inhibit themigration and invasion of these cancer
cells in vitro [56] and in vivo [33]. An in situ analysis of cell metabolism
indicated that both pristine graphene and GO decreased the electron
transfer chain activity and caused a reduction in the production of ATP,
which impaired the assembly of the actin cytoskeleton that is crucial
for the migration and invasion of metastatic cancer cells [56].
Using systems biology-based approaches, Zhou and coworkers
compared the differentially expressed proteins in cancer cells and non-
cancerous epithelial cells exposed to GO. Interestingly, GO selectively
targeted the key switch molecule of the cell metabolism, PGC-1α, in
breast cancer cells, and down-regulated the expression of its effector
genes, including the core subunits of the OXPHOS complex. Thus, GO
was shown to remodel the metabolism of cancer cells [33].
5.4. Biological effects on stem cells
Based on their controllable biocompatibility, graphene and graphene-
related nanomaterials could be used in tissue engineering, and thus the
interaction between graphene and stem cells is an important research
160 B. Zhang et al. / Advanced Drug Delivery Reviews 105 (2016) 145–162area. Kim and coworkers summarized the potential of graphene or its de-
rivatives for stemcell applications,with a particular focus onguiding stem
cell differentiation, effective monitoring of their differentiation, stem cell
delivery/transplantation, and promoting stem cell growth [100]. For ex-
ample,MSChas emerged as a potentialmodality formyocardial infarction
treatment through the secretion of paracrine factors and a gap junction
protein to promotes cardiac repair and function restoration. Park and co-
workers incorporates ﬁbronectin-adsorbed rGO ﬂakes into MSC spher-
oids, which enhances the cell-extracellular matrix (ECM) interactions,
increases the paracrine factor expression, and up-regulates gap junction
protein connexin 43. The injection of MSC-rGO hybrid spheroids into
the infarcted hearts enhances cardiac repair compared with the injection
of rGO ﬂakes or MSC spheroids (Fig. 9) [101]. Park and coworkers also
uses the GO ﬂakes to protect the implanted MSCs from ROS-mediated
death and thereby improve the therapeutic efﬁcacy of the MSCs [102].
These effect likely due to the high afﬁnity toward ECM proteins and the
electrical conductivity of rGO and GO. These studies demonstrate that
graphene can effectively improve the therapeutic efﬁcacy, such as MSCs
for ischemic heart diseases. Progression of effects on stem cells will
promote and accelerate the use of graphene-based materials for stem
cell-based approaches to cure various incurable diseases/disorders.
6. Conclusions, challenges, and future perspectives
Since its discovery in 2004, signiﬁcant advances have been made in
the development of graphene and graphene-related materials. They
have exhibited a wide range of potential applications in different ﬁelds
including electronics, energy engineering, and biomedicine. Recently,
the number of biological studies involving graphene-related materials
has rapidly increased, in which the effects of the biological interactions
between graphene and living systemswere documented. In the present
review, we focuses on the molecular mechanisms underlying the inter-
actions between graphene-related nanomaterials and cells and provides
a systematic review of how graphene may interact with biomolecules,
cross the plasma membrane, translocate within the endosome/
lysosome systems, and affect key cellular components including mito-
chondrion, nucleus, and cytoskeleton (Table 1).
The interaction betweengraphene-related nanomaterials andplasma
membrane and its transportation across the plasma membrane are key
steps involved in the induction of biological effects, which are closely
related with the physicochemical properties of graphene, including
size, shape, and surface chemistry. By manipulating these properties,
we can enhance the transportation efﬁcacy of graphene-related
materials, and diminish their side-effects. For example, small-sized
(nano-sized) graphene derivatives with moderate oxidation status are
generally more prone to be internalized into cells via endocytosis;
based on these intrinsic properties, nano-sized GO derivatives could be
used as efﬁcient drug or gene carriers. The cytotoxicity effects of
graphene-related materials could also be mitigated by surface modiﬁca-
tion with biocompatible molecules (e.g. natural proteins, peptides, and
sugars).
This review also provided important information about the interac-
tions between graphene-related nanomaterials and their effector cells,
including immune cells, cancer cells, and stem cells. After their adminis-
tration into the body, graphene-related materials cause a complicated
impact on the immune system. On one hand, graphene could activate
the macrophages and thus induce an immunoactivation response; on
the other hand, high concentration of graphene could also induce apo-
ptosis in macrophages and induce an immunosuppression response.
Physicochemical properties of graphene-related materials, including
size, shape, and surface chemistry, determine the immune responses;
accordingly, graphene-related materials may act as immunotherapy
tools after a suitable surface modiﬁcation.
Cancer therapy is one of the hottest topics in the biomedical applica-
tion of graphene-related nanomaterials. Due to their small size, large
surface area, and versatile chemistry, graphene-related materials areregarded as ideal building blocks for drug carrier, which tend to selec-
tively accumulate in tumor tissue owing to the enhanced permeability
and retention effect. Information about the interactions between
graphene and cancer cells provides new strategies for selective targeting
graphene to cancer cells. For example, cancer cell-speciﬁc uptake of
graphene could be further improved by modiﬁcation with various
targeting molecules, include folic acid, antibodies, DNA aptamers, trans-
ferrin, and peptides. By integrating chemotherapy agents, photothermal
therapy agents, and multimodal imaging probes on the graphene core,
multifunctional nanoplatforms for cancer theragnosis have been suc-
cessfully developed.
Based on the information about the interactions between graphene
and stem cells, a series of engineered graphene-related nanomaterials
with improved high biocompatibility have been developed, which show
promising potential in the ﬁelds of tissue engineering and regenerative
medicine. Proper surface engineering endow graphene with a strong
adsorbing capacity for both small molecules and biomacromolecules,
which are essential for the growth and differentiation of stem cells.
Although the toxicity of graphene-related materials in vitro and
in vivo could be mitigated by controlling the size, shape, and surface
chemistry, the long-term toxicity is still a crucial issue. However, knowl-
edge about the biodegradation and metabolism of graphene-related ma-
terials is still limited. The design and development of biodegradable
graphene derivatives through optimizing the physicochemical properties
and structural modiﬁcation is an important step to obtain graphene-
related materials with excellent biocompatibility and biosafety, which
will satisfy the clinical requirements in nanomedicine in the future.
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